Accretion Pharmaceuticals Limited

Accretion Pharmaceuticals Limited (ACCPL) is a micro-cap Healthcare company valued at ₹215 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Accretion Pharmaceuticals Limited last traded at ₹193.2, unchanged on the day.

Recent developments

2026-06-30: Domestic institutional holding increased by 2.76 percentage points to 2.76%. 2026-06-30: Promoter holding remained at 73.52%. 2026-06-30: The company continued to report profits without paying dividends.

Financial performance

The company's business is improving, with annual revenue rising 56.2% and annual net profit growing 42.4%. The latest quarter saw revenue increase 18.2% and net profit rise 13.6% compared to the same quarter a year earlier. However, the net profit margin narrowed by 1.0 percentage points to 10.8%, while return on equity remained stable at 17.7%.

Valuation multiples

The stock trades at 21.4 times earnings, a discount to the Healthcare median of 32.0, 4.27 times book value.

Things to watch

The stock is 7.6% below its 52-week high. The net profit margin has narrowed by 1.0 percentage points. The company has not paid dividends despite reporting profits.

Where it stands

Accretion Pharma Limited has shown strong revenue and profit growth over the past three years, with revenue growing 45.0% annually and net profit rising 359.0% annually. The latest quarter saw continued growth in both revenue and net profit, but the net profit margin has declined. The stock is currently 7.6% below its 52-week high.

Summarised by DocStoX's model on 2026-10-04 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.